Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Preoperative fluorodeoxyglucose positron emission tomography-computed tomography in papillary thyroid cancer: a futile exercise.

Garg PK.

J Int Med Res. 2014 Feb;42(1):243-4. doi: 10.1177/0300060513516945. Epub 2013 Dec 17. No abstract available.

PMID:
24345825
2.

The value of preoperative PET-CT in papillary thyroid cancer.

Kim BS, Ryu HS, Kang KH.

J Int Med Res. 2013 Apr;41(2):445-56. doi: 10.1177/0300060513475743. Epub 2013 Feb 5.

PMID:
23569010
3.

Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.

Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, Berdelou A, Lepoutre-Lussey C, Mirghani H, Baudin E, Schlumberger M, Leboulleux S.

Thyroid. 2015 Apr;25(4):437-44. doi: 10.1089/thy.2014.0320. Epub 2015 Mar 16.

PMID:
25633259
4.

Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management.

Schreinemakers JM, Vriens MR, Munoz-Perez N, Guerrero MA, Suh I, Rinkes IH, Gosnell J, Shen WT, Clark OH, Duh QY.

World J Surg Oncol. 2012 Sep 17;10:192. doi: 10.1186/1477-7819-10-192.

5.

Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.

Weber T, Ohlhauser D, Hillenbrand A, Henne-Bruns D, Reske SN, Luster M.

Horm Metab Res. 2012 Nov;44(12):904-8. doi: 10.1055/s-0032-1316351. Epub 2012 Jul 12.

PMID:
22791600
6.

Comparison of 18F-fluorodeoxyglucose uptake with the expressions of glucose transporter type 1 and Na+/I- symporter in patients with untreated papillary thyroid carcinoma.

Moon SH, Oh YL, Choi JY, Baek CH, Son YI, Jeong HS, Choe YS, Lee KH, Kim BT.

Endocr Res. 2013;38(2):77-84. doi: 10.3109/07435800.2012.713426. Epub 2012 Aug 13.

PMID:
22888973
7.

Evaluation of rare choroid plexus metastasis from papillary thyroid carcinoma with multimodality imaging.

Manzil FF, Bender LW, Scott JW.

Clin Nucl Med. 2014 Jun;39(6):551-3. doi: 10.1097/RLU.0b013e31829f913d.

PMID:
23877529
8.

[Occult papillary thyroid carcinoma in thyroglossal cyst diagnosed by (18)FDG PET/CT scan].

Serrano Vicente J, Infante Torre JR, Rayo Madrid JI, García Bernardo L, Domínguez Grande ML, Durán Barquero C, Sánchez Sánchez R.

Rev Esp Med Nucl Imagen Mol. 2012 Jul-Aug;31(4):229-30. doi: 10.1016/j.remn.2012.01.006. Epub 2012 May 6. Spanish. No abstract available.

9.

Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.

Kim MH, O JH, Ko SH, Bae JS, Lim DJ, Kim SH, Baek KH, Lee JM, Kang MI, Cha BY, Lee KW.

Thyroid. 2012 Feb;22(2):157-64. doi: 10.1089/thy.2011.0177. Epub 2012 Jan 6.

PMID:
22224820
10.

Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma.

Kim BS, Kim SJ, Kim IJ, Pak K, Kim K.

Thyroid. 2012 Jul;22(7):725-9. doi: 10.1089/thy.2011.0031. Epub 2012 Apr 23.

11.

Positron emission tomography detected thyroid incidentaloma.

Goddard J, Gaunt A, Markham DH.

Ann R Coll Surg Engl. 2013 Jan;95(1):e3-4. doi: 10.1308/003588413X13511609956732.

12.

Clinicopathologic characteristics of synchronous primary thyroid cancer detected by initial staging 18F-FDG PET-CT examination in patients with underlying malignancy.

Kim BH, Lee CH, Kim SJ, Jeon YK, Kim SS, Kim YK, Kim IJ.

Thyroid. 2013 Nov;23(11):1431-6. doi: 10.1089/thy.2012.0546. Epub 2013 Jul 25.

13.

Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.

Kim MH, Ko SH, Bae JS, Lee SH, Jung CK, Lim DJ, Baek KH, Kim SH, Lee JM, Kang MI, Cha BY.

Thyroid. 2013 Nov;23(11):1452-60. doi: 10.1089/thy.2013.0051. Epub 2013 Sep 19.

PMID:
23688271
14.

High FDG and low FLT uptake in a thyroid papillary carcinoma incidentally discovered by FDG PET/CT.

Nakajo M, Nakajo M, Kajiya Y, Jinguji M, Mori S, Aridome K, Suenaga T, Tanaka S.

Clin Nucl Med. 2012 Jun;37(6):607-8. doi: 10.1097/RLU.0b013e318252d80f.

PMID:
22614200
15.
16.

Thyroid incidentaloma detected by fluorodeoxyglucose positron emission tomography/computed tomography: practical management algorithm.

Nilsson IL, Arnberg F, Zedenius J, Sundin A.

World J Surg. 2011 Dec;35(12):2691-7. doi: 10.1007/s00268-011-1291-4.

PMID:
21989645
17.

Prediction of central lymph node metastasis from papillary thyroid microcarcinoma by 18F-fluorodeoxyglucose PET/CT and ultrasonography.

Byun BH, Jeong UG, Hong SP, Min JJ, Chong A, Song HC, Bom HS.

Ann Nucl Med. 2012 Jul;26(6):471-7. doi: 10.1007/s12149-012-0594-3. Epub 2012 Mar 31.

PMID:
22467230
18.

¹⁸F-FDG and new positron emitter radiotracers for detecting recurrent medullary thyroid carcinoma.

Marzola MC, Rubello D.

J Med Imaging Radiat Oncol. 2012 Apr;56(2):132-5. doi: 10.1111/j.1754-9485.2012.02353.x. No abstract available.

PMID:
22498183
19.

Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.

Dennis K, Hay JH, Wilson DC.

Clin Oncol (R Coll Radiol). 2012 Dec;24(10):e168-72. doi: 10.1016/j.clon.2012.08.002. Epub 2012 Sep 1.

PMID:
22944464
20.

Primary squamous cell carcinoma of the thyroid on FDG PET/CT.

Cai L, Chen Y, Huang Z, Wu J.

Clin Nucl Med. 2014 Nov;39(11):1014-6. doi: 10.1097/RLU.0000000000000511.

PMID:
24999700

Supplemental Content

Support Center